FDA has granted IDE approval for the STROKE-REWIRE pivotal trial evaluating NeuWire Medical's neurostimulation device for chronic ischemic stroke recovery.
News|Slideshows|May 14, 2020
COVID-19 Consequences: Takeaways from a Mental Health Survey of US Adults
Author(s)Sydney Jennings
Over half of US adults who responded to a new survey said COVID-19 has impacted their mental health. To what extent? Find out in our new slideshow.
Advertisement
In honor of May being National Mental Health Awareness Month,
Advertisement
Related to this article
Catch up on the 9 FDA drug approvals most relevant to primary care, including new options for HIV-1 infection, narcolepsy, diabetes, pain management, and more.
Stroke incidence in adults aged 20–54 nearly doubled from 1993–1994 to 2020, driven largely by ischemic stroke, while 30-day fatality declined, according to new research.
FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
A team-based blood pressure intervention delivered through primary care reduced dementia risk by 15% over 7 years.
Physical activity was associated with up to 22% lower mortality and 19% lower stroke risk in adults with and without atrial fibrillation in a large Norwegian cohort study.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
Advertisement
Advertisement
Trending on Patient Care Online
1
FDA Approves Once-Monthly Olanzapine Injection for Adults With Schizophrenia
2
Abbott Gains FDA Approval for CardioMEMS Update Letting Heart Failure Patients View Pressure Readings on Their Phones
3
Multicomponent Strategies to Ease Vaccination Pain and Fear Across Ages
4
FDA Clears IDE for NeuWire Medical's STROKE-REWIRE Trial in Chronic Ischemic Stroke
5